New Research Offers Hope for Stargardt Disease Treatment

Promising Preclinical Data and Key Insights Shared at ARVO 2026

Stargardt disease, the most common form of inherited macular degeneration, is a progressive condition that leads to central vision loss, often beginning in childhood or adolescence. For individuals and families affected by this inherited retinal disease (IRD), the prospect of effective treatments is a constant hope. Recent presentations at the ARVO 2026 Annual Meeting have brought encouraging news, highlighting innovative approaches in the pipeline.

City Therapeutics Unveils Next-Generation RNAi Therapy

City Therapeutics presented promising preclinical data for their investigational RNA interference (RNAi) therapy, CITY-RBP4, at the ARVO 2026 Annual Meeting. RNAi therapies work by silencing specific genes, and CITY-RBP4 is designed to target the RBP4 gene. The RBP4 gene is responsible for producing retinol-binding protein 4, which plays a role in vitamin A transport. In Stargardt disease, mutations in the ABCA4 gene lead to the accumulation of toxic byproducts in the retina, primarily due to issues with vitamin A metabolism.

By modulating RBP4, CITY-RBP4 aims to reduce the excessive accumulation of these toxic vitamin A derivatives, which are believed to contribute to retinal damage and vision loss in Stargardt patients. The preclinical data shared by City Therapeutics suggests that this novel approach could offer a new therapeutic avenue for slowing or preventing the progression of the disease. This represents a significant step in developing targeted treatments for Stargardt disease.

Alkeus Pharmaceuticals Shares Key Data

Also at ARVO 2026, Alkeus Pharmaceuticals presented key data related to Stargardt disease. While specific details about Alkeus's presentation were not immediately available, their presence and the focus on Stargardt disease underscore the growing momentum in research for this condition. Alkeus has been previously recognized for its work on ALK-001 (deuterated vitamin A), an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina, similar in principle to the goals of CITY-RBP4 but through a different mechanism.

The presentation of